STELARA®: Unique 4 PsA

A therapy for the uniqueness of active psoriatic arthritis1,2

STELARA® (ustekinumab) Mechanism of Action: Psoriatic Arthritis
  • STELARA® is a human IgG1k monoclonal antibody that binds with specificity to the p40 protein subunit used by both the IL-23 and IL-12 cytokines1,2
  • STELARA® has a unique mechanism of action as the only available biologic that selectively targets IL-23 and IL-12 cytokines2
  • IL-23 and IL-12 are naturally occurring cytokines that are involved in inflammatory and immune responses, such as natural killer cell activation and CD4+ T-cell differentiation and activation1
  • In in vitro models, STELARA® was shown to disrupt IL-23 and IL-12 mediated signaling and cytokine cascades by disrupting the interaction of these cytokines with a shared cell-surface receptor chain, IL-12Rß11   
  • The clinical significance of these characteristics is not fully known


By targeting the upstream regulatory cytokines IL-23 and IL-12, STELARA® was shown to disrupt the resultant inflammatory cascade.1

Mechanism of Disease: Psoriatic Arthritis
  • PsA is a chronic inflammatory disease characterized by both skin and joint involvement3
  • Genetic studies have identified links with both IL23 and IL12ß, implying a central role of the IL-23/IL-12 inflammatory gateway in the pathology of PsA4,5
  • Activation of the IL-23/IL-12 pathway results in the production of proinflammatory cytokines that, in turn, are thought to exert effects on the respective target organs to produce the clinical manifestations of PsA6-8


References: 1. STELARA [package insert]. Horsham, PA: Janssen Biotech, Inc; 2016. 2. McInnes IB, Kavanaugh A, Gottlieb AB, et al; for the PSUMMIT 1 Study Group. Efficacy and safety of ustekinumab in patients with active psoriatic arthritis: 1 year results of the phase 3, multicentre, double-blind, placebo-controlled PSUMMIT 1 trial. Lancet. 2013;382(9894):780-789. 3. Cauli A, Mathieu A. Th17 and interleukin 23 in the pathogenesis of psoriatic arthritis and spondyloarthritis. J Rheum. 2012;39(89):15-18. 4. Bowes J, Orozco G, Flynn E, et al. Confirmation of TNIP1 and IL23A as susceptibility loci for psoriatic arthritis. Ann Rheum Dis. 2011;70:1641-1644. 5. Filer C, Ho P, Smith RL, et al. Investigation of association of the IL12B and IL23R genes with psoriatic arthritis. Arthritis Rheum. 2008;58(12):3705-3709. 6. Raychaudhuri SP. Role of IL-17 in psoriasis and psoriatic arthritis. Clin Rev Allergy Immunol. 2013;44:183-193. 7. Smith JA, Colbert RA. The interleukin-23/interleukin-17 axis in spondyloarthritis pathogenesis: Th17 and beyond. Arthritis Rheum. 2014;66:231-241. 8. Maeda S, Hayami Y, Naniwa T, et al. The Th17/IL-23 axis and natural immunity in psoriatic arthritis. Int J Rheumatol. 2012. doi:10.1155/2012/539683.